Introduction
============

Takayasu\'s arteritis (TAK), also known as \"pulseless disease,\" is a chronic granulomatous panarteritis characterized by the involvement of large vessels, especially the aorta and its major branches \[[@B1],[@B2]\]. Although the etiology of TAK is still unknown, infectious agents, genetic factors and autoimmunity are thought to play a major role in its pathogenesis \[[@B3]\]. Cell-mediated autoimmunity has been implicated in the physiopathology of vascular cell injury in TAK. In addition to γδ T cells, natural killer (NK) cells and macrophages, tissue specimens from the aortas of TAK patients are infiltrated with T cells that have a restricted T-cell repertoire, which is typical of antigen-induced proliferation \[[@B4]-[@B6]\].

Evidences of genetic susceptibility to TAK have previously been demonstrated for SNPs of cytokine genes such as IL-2, IL-6 and IL-12 and the *NFKBIL1*promoter region \[[@B7],[@B8]\], but not with autoimmunity associated genes such as *PTPN22*\[[@B9]\] and *PDCD1*\[[@B10]\]. Genes encoding human leukocyte antigen (HLA) are highly polymorphic, show remarkable ethnic and geographic differences in allele and haplotype frequencies and are natural candidates for genetic susceptibility to immune and inflammatory diseases. Although some associations with class II alleles such as *HLA-DRB\*1301*have been reported, studies from mainly East Asian countries have demonstrated *HLA-B\*52*as the main risk factor in the HLA region \[[@B11],[@B12]\]. However, this association has not been confirmed in North American and Arab populations \[[@B13],[@B14]\].

*HLA-B\*51*and *HLA-B\*52*are two *HLA-B*allele groups with only two amino acid differences \[[@B15]\]. However, *HLA-B\*51*is associated with a phenotypically separate vasculitis, namely, Behçet\'s disease \[[@B16]\]. Previously, associations of both major HLA-B subtypes *HLA-B\*51*and *HLA-B\*52*with TAK have been shown only in an Indian population \[[@B17]\]. On the basis of this background, we screened patients with TAK in Turkey for the presence of *HLA-B\*51*and *HLA-B\*52*.

Materials and methods
=====================

The study was designed as a case-control study. We enrolled 330 patients with TAK (42 men and 288 women, mean age 38.9 ± 12.2 years) of mixed ethnic origin from Turkey. The patients were referred from 15 tertiary university and state hospital rheumatology centers in Turkey. Patients were classified according to the 1990 American College of Rheumatology criteria for TAK \[[@B18]\]. According to the angiographic classification scheme defined at the International Conference on Takayasu\'s Arteritis in Tokyo, 39.4% (*n*= 130) of the patients had type I vessel involvement, 6.4% had type IIa (*n*= 21), 2.7% had type IIb (*n*= 9), 3.9% had type III (*n*= 13), 4.5% had type IV (*n*= 15) and 43% had type V (*n*= 142) \[[@B19]\]. A surgical procedure was performed in 21.1% of the patients, with 11.6% done after immunosuppressive (IS) therapy. Patients with late-onset (\> 40 years of age) disease was present in 23.8% of the patients. Corticosteroid treatment was given to 95% of the patients, standard first-line ISs (methotrexate, azatioprine, leflunomide or cyclophosphamide) were administered to 94.5% and second-line ISs (TNF antagonists) were given to 3.5%.

To evaluate HLA-disease phenotype associations, our study group proposed a consensus definition of \"refractory disease\" for TAK. Patients with \"angiographic or clinical progression despite treatment\" or any of the following characteristics were accepted to have \"refractory\" disease: corticosteroid dose \> 7.5 mg/day after 6 months of treatment, despite the administration of conventional ISs (methotrexate, azatioprine, leflunomide or cyclophosphamide); new surgery due to persistent disease activity; frequent attacks (more than three yearly); or death associated with disease activity. On the basis of this definition, 27.4% (*n*= 114) of the patients with sufficient follow-up for analysis had refractory disease. Eighteen patients (5.9%) died during follow-up.

A total of 210 healthy blood donors (97 men and 113 women, mean age 32.2 ± 10.9 years) with the same mixed ethnic origin from Turkey were recruited for participation as healthy controls (HCs). All patients and controls were enrolled with the approval of the Marmara University Medical School Local Ethics Committee and provided their informed consent.

Genotyping
----------

For genotyping, cellular DNA was isolated from peripheral blood using standard procedures. For the determination of *HLA-B\*52*and *HLA-B\*51*alleles, DNA was amplified using the forward primers HLA 192 and HLA 193, respectively, and reverse primer HLA 216 (for both) for the specific product with another pair of primers was used as a control product \[[@B20]\]. PCR amplification was carried out in NH~4~buffer with 1.3 mM MgCl~2~, 0.2 μM deoxyribonucleotide triphosphate, 0.5 μM of each primer, 60 ng of genomic DNA and 1 IU of *Taq*polymerase. The cycling parameters were as follows: an initial denaturation step of 2 minutes at 95°C; 5 cycles of 20 seconds at 95°C, 60 seconds at 64°C and 20 seconds at 72°C followed by 25 cycles of 20 seconds at 95°C, 60 seconds at 63°C and 20 seconds at 72°C; and a final extension step of 2 minutes at 72°C. Products were run on 1.5% agarose gel stained with ethidium bromide.

Statistical analysis
--------------------

HLA alleles in TAK patients were compared with those of the HCs and within the patient group. The strength of the association was expressed by the OR, and the statistical significance was examined by χ^2^test.

Results
=======

We found a significant association of *HLA-B\*52*with TAK (20.9% of patients (69 of 330) vs 6.7% of HCs (14 of 210), *P*= 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The association of *HLA-B\*52*with TAK was noted in women (21.5% vs 7.1%, *P*= 0.000, OR = 3.6, 95% CI = 1.66 to 7.79), but did not reach significance in men (16.7% vs 6.2%, *P*= 0.063). The distribution of *HLA-B\*51*did not differ between TAK patients and controls (22.7% of patients (75 of 330) vs 24.8% of HCs (52 of 210), *P*= 0.3, OR = 0.9, 95% CI = 0.60 to 1.34).

When we investigated *HLA-B\*52*presence according to the onset of disease, a decreased presence of *HLA-B\*52*was observed in late-onset patients (\> 40 years of age) (early onset 24.2% vs late onset 12.0%, *P*= 0.024, OR = 0.43, 95% CI = 0.20 to 0.91) (Table [1](#T1){ref-type="table"}). We then investigated whether the presence of *HLA-B\*52*affects the disease phenotype. Although we observed that the frequency of *HLA-B\*52*was significantly higher in all disease subtypes than in HCs, a lower presence of *HLA-B\*52*was present in patients with type I disease (13.1%) (*P*= 0.005, OR = 0.43, 95% CI = 0.24 to 0.78) compared to all other types of vessel involvement (types IIa through V, 26%). Although the finding did not reach statistical significance, patients defined as having refractory disease also seemed to have a stronger association with *HLA-B\*52*(refractory 27.4% vs nonrefractory 18.1%, *P*= 0.84, OR = 1.68, 95% CI = 0.97 to 2.93). No association of surgery and IS drug requirement after surgery with *HLA-B\*52*presence was present (surgery *HLA-B\*52*13.6% vs 21.6%, *P*= 0.092, OR = 0.51, 95% CI = 0.24 to 1.09; IS after surgery *HLA-B\*52*19.4% vs 21.6, *P*= 1.0). No association of *HLA-B\*51*presence was observed with gender, age, disease phenotype, treatment or any other clinical feature of TAK (Table [1](#T1){ref-type="table"}).

###### 

Distribution of *HLA-B\*51*and *HLA-B\*52*allele groups in healthy controls and Takayasu\'s arteritis patients^a^

  Characteristics              *n*   *HLA-B\*52*+ (%)   *P*     OR (95% CI)           *HLA-B\*51*+ (%)   *P*
  ---------------------------- ----- ------------------ ------- --------------------- ------------------ ------
  HC                           210   14 (6.7)                                         52 (24.8)          
   Men                         97    6 (6.2)                                          23 (23.7)          
   Women                       113   8 (7.1)                                          29 (25.7)          
  TAK                          330   69 (20.9)          0.000   3.7 (2.02 to 6.77)    75 (22.7)          0.64
   Men                         42    7 (16.7)           0.063                         12 (28.6)          0.53
   Women                       288   62 (21.5)          0.000   3.6 (1.66 to 7.79)    63 (21.9)          0.43
  Age at onset                                                                                           
   \< 40 years                 240   58 (24.2)          0.024   0.43 (0.20 to 0.91)   49 (20.4)          0.11
   ≤ 40 years                  75    9 (12.0)                                         22 (29.3)          
  Angiographic subtype^b^                                                                                
   Type I                      130   17 (13.1)          0.005   0.43 (0.23 to 0.78)   28 (21.5)          0.78
   Type Iia                    21    8 (38.1)                                         6 (28.6)           
   Type Iib                    9     3 (33.3)                                         2 (22.2)           
   Type III                    13    5 (38.5)                                         3 (23.1)           
   Type IV                     15    3 (20.0)                                         1 (6.7)            
   Type V                      142   34 (23.9)                                        35 (24.6)          
  Surgery (all)                                                                                          
   Present                     66    9 (13.6)           0.092   0.51 (0.24 to 1.09)   13 (19.7)          0.62
   Not present                 246   58 (23.6)                                        57 (23.2)          
  Surgery after IS treatment                                                                             
   Present                     36    7 (19.4)           1.0                           9 (25)             0.67
   Not present                 273   59 (21.6)                                        60 (22.0)          
  Refractory disease                                                                                     
   Refractory                  114   31 (27.4)          0.084   1.68 (0.97 to 2.93)   20 (17.5)          0.12
   Not refractory              193   35 (18.1)                                        49 (25.4)          

^a^HC, healthy control; IS, immunosuppressive; TAK, Takayasu\'s arteritis. Subgroup analysis was performed between groups with or without known clinical features. ^b^*P*vs other all other subtypes.

Discussion
==========

Researchers in various previous studies have demonstrated a strong association of *HLA-B\*52*in TAK. Our first study from Turkey, with a relatively large sample, has confirmed this association. No association of *HLA-B\*51*with TAK was present in this series.

The highest presence of *HLA-B\*52*in TAK was previously reported in a Japanese population (41%, RR = 2.2) \[[@B11]\]. In Japan, *HLA-B\*52*is also associated with aortic insufficiency, ischemic heart disease and pulmonary involvement \[[@B21]\]. We observed no association with these clinical features in our series. However, the routine use of ISs in our patients might have affected our results. Features of a more severe and refractory disease are also associated with *HLA-B\*52*presence in Japan: higher blood pressure, acute phase response and corticosteroid requirement \[[@B22],[@B23]\]. Interestingly, we also observed a mild association of *HLA-B\*52*with more extensive aortic disease and refractoriness to treatment, which might suggest an association of *HLA-B\*52*with a more severe disease spectrum.

Studies from East Asian countries such as Korea, Thailand and India confirmed a *HLA-B\*52*association with TAK, though usually with a lower prevalence than Japan (Thailand and Korea both 15%) \[[@B12],[@B24]\]. The lower presence of *HLA-B\*52*in patients with TAK might be associated with the lower prevalence in the background HCs (*HLA-B\*52*in HCs in Japan 23%, in Thailand 2.3% and in Turkey 6.7%). Association of *HLA-B\*52*with TAK has also been reported in other ethnic groups, such as Mexicans and Greeks \[[@B25],[@B26]\]. Lack of association in North America and Arab populations requires confirmatory studies, as the number of samples has been too low in these studies to draw any conclusions \[[@B13],[@B14]\].

Late-onset TAK (\> 40 years of age) poses difficulties in the differential diagnosis from giant cell arteritis (GCA), and the two diseases are suggested to be a continuum with overlapping features \[[@B27]\]. In this context, *HLA-B\*52*might be a specific genetic susceptibility factor for classic early-onset TAK, as no association of GCA with *HLA-B\*52*has been reported previously \[[@B28]\].

Associations with other HLA genes in patients from Korea (*HLA-A\*3001, HLA-DRB1\*1502*) and Mexico (*HLA-DRB1\*1301*) have also been reported; however, they have not been confirmed in other populations \[[@B29],[@B30]\]. Although regions close to *HLA-B*, such as major histocompatibility complex class I-related chain A, have also been investigated for linkage disequilibrium in Japan, no further association has been confirmed \[[@B31]\]. An association of *HLA-B\*3901*with TAK has also been reported in studies conducted in Japan and Mexico \[[@B32],[@B33]\]. However, this association has not been confirmed in India, Greece or Korea \[[@B17],[@B26],[@B29]\]. We also previously looked at *HLA-B\*39*in a subset of our population and observed no association with TAK (2.9% vs. 3.6%) (unpublished observation, M. Bicakcigil, et al).

The lack of association of *HLA-B\*51*with TAK, a granulomatous vasculitis, has important implications for the pathogenesis of TAK. As *HLA-B\*51*(a very common allele in Turkey) is associated only with Behçet\'s disease, an inflammatory disease involving the activation of both innate and adaptive immunity, peptide-binding differences of *HLA-B\*51*and *HLA-B\*52*seem to predispose patients to very different clinical phenotypes of vasculitis \[[@B34]\]. Moreover, the association of *HLA-B\*52*seem to be weaker in Turkish TAK patients compared to the *HLA-B\*51*-Behçet\'s association, suggesting that other genetic factors might have a larger effect on disease susceptibility in TAK \[[@B35]\].

Our study has some limitations. All patients were followed in tertiary centers and may reflect a more severe disease spectrum. As TAK is a rare disease, however, we think that most patients suspected or diagnosed as having TAK are referred to specialized centers in Turkey. The gender ratio among TAK patients and HCs was not well-matched in our study. Finally, we chose to study only the *HLA-B*types previously associated with TAK, and other alleles need to be studied as well.

Conclusion
==========

We have confirmed the association of the *HLA-B\*52*allele with TAK in patients in Turkey. The negative association with late-onset and milder forms of the disease needs to be confirmed in other populations.
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